Roche on efficacy and safety of risdiplam in patients with type 2/3 sp

Roche on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020

Agenda:

Welcome

Phase II/III SUNFISH part 2 data - efficacy and safety of risdiplam in patients with type 2 or type 3 SMA

Q&A

Karl Mahler, Head of Investor Relations

Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development

First Name

Last name

Corporate Email

Company Name

Confirm you are a human *

Roche has hosted a live audio webcast and conference call on Thursday, 6 February 2020.

Investors

Downloads

PDF